Related Experiment Video

Updated: Jan 22, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.2K

Disopyramide for Hypertrophic Cardiomyopathy

Alejandro Sanchez-Nadales1, Andrea Anampa-Guzmán2, Amir Khan1

  • 1Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, USA.

Cureus
|July 3, 2019
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) is a heart condition causing thickened ventricles. This case study shows disopyramide effectively improved symptoms in an obstructive HCM patient resistant to other treatments.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease.
  • Obstructive HCM presents with left ventricular hypertrophy and can lead to sudden cardiac death.
  • Symptoms are often refractory to standard medical management.

Observation:

  • A female patient diagnosed with obstructive HCM presented with severe symptoms.
  • Her condition was resistant to conventional medical therapies.
  • The patient opted against invasive procedures for treatment.

Findings:

  • Disopyramide was administered as an additional therapeutic agent.
  • The patient experienced significant improvement in HCM symptoms after disopyramide initiation.
  • Disopyramide demonstrated efficacy in managing obstructive HCM.

Implications:

  • Disopyramide offers a safe and effective non-invasive treatment option for obstructive HCM.
  • This medication can alleviate symptoms and potentially delay the need for invasive interventions.
  • Further research into disopyramide's role in HCM management is warranted.

Keywords:
cardiomyopathyhypertrophicmyosin

More Related Videos

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring05:54

A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring

Published on: November 29, 2024

2.1K
In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding08:20

In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding

Published on: May 1, 2020

7.1K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
433
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
492
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
488
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
521
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
321
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
361